Genmab A (GMAB) Enterprise Value (2018 - 2026)
Genmab A's (GMAB) quarterly Enterprise Value came in at -$1.5 billion in Q1 2026, up 10.48% YoY from -$1.4 billion in Q1 2025, and up 11.31% on a QoQ basis from -$1.7 billion in Q4 2025.
Genmab A (GMAB) Enterprise Value (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 7 years of Enterprise Value data on file, last reported at -$1.5 billion in Q1 2026.
- Quarterly Enterprise Value rose 10.48% year-over-year to -$1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.5 billion (up 10.48% YoY) and the FY2025 annual result came in at -$1.7 billion, up 41.94% from the prior year.
- Enterprise Value rose to -$1.5 billion in Q1 2026, from -$1.7 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$43.0 million in Q3 2024 to a low of -$2.9 billion in Q2 2025.
- A 4-year average of -$1.4 billion and a median of -$1.6 billion in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value jumped 42.14% — and 2025, when it slumped 4320.93%.
- Tracing GMAB's Enterprise Value over 4 years: stood at -$2.4 billion in 2023, then surged by 42.14% to -$1.4 billion in 2024, then decreased by 23.29% to -$1.7 billion in 2025, then gained by 11.31% to -$1.5 billion in 2026.
- The last three Enterprise Value figures came in at -$1.5 billion (Q1 2026), -$1.7 billion (Q4 2025), and -$1.9 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | -1.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.50 Bn |
| Mar 31, 2026 | -1.52 Bn |
| Dec 31, 2025 | -1.72 Bn |
| Sep 30, 2025 | -1.90 Bn |
| Jun 30, 2025 | -2.90 Bn |
| Mar 31, 2025 | -1.70 Bn |
| Dec 31, 2024 | -1.39 Bn |
| Sep 30, 2024 | -43.00 Mn |
| Jun 30, 2024 | -624.00 Mn |
| Mar 31, 2024 | -130.00 Mn |
| Dec 31, 2023 | -2.40 Bn |
| Sep 30, 2020 | -8,892,000.00 Bn |
| Dec 31, 2019 | -4,643.00 |
| Sep 30, 2019 | -4.64 Bn |
| Dec 31, 2018 | -896.07 Mn |